High-Flow Nasal Oxygen Therapy as an Adjunct Treatment in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

EasyChair Preprint no. 13686

Abstract

High-flow nasal oxygen (HFNO) therapy has emerged as a promising adjunct treatment in managing chronic obstructive pulmonary disease (COPD) exacerbations. COPD exacerbations, characterized by acute worsening of respiratory symptoms, often lead to significant morbidity, frequent hospitalizations, and increased healthcare costs. Traditional management strategies, including bronchodilators, corticosteroids, and antibiotics, have shown efficacy; however, the integration of HFNO therapy offers additional benefits. This therapy delivers heated, humidified oxygen at high flow rates, enhancing oxygenation and reducing the work of breathing.

Recent studies indicate that HFNO therapy can improve gas exchange, decrease respiratory rate, and enhance patient comfort compared to conventional oxygen therapy. Furthermore, HFNO therapy may reduce the need for invasive mechanical ventilation, thereby decreasing associated complications and mortality. This abstract aims to review the current evidence on HFNO therapy's efficacy, safety, and potential mechanisms of action in treating COPD exacerbations. By exploring the physiological benefits and clinical outcomes, this review seeks to establish HFNO therapy as a critical component in the comprehensive management of COPD exacerbations, highlighting its role in improving patient outcomes and optimizing respiratory care.

Keyphrases: Chronic Obstructive Pulmonary Disease (COPD), High-flow nasal oxygen (HFNO), management strategies

@Booklet{EasyChair:13686,
  author = {Abill Robert},
  title = {High-Flow Nasal Oxygen Therapy as an Adjunct Treatment in Chronic Obstructive Pulmonary Disease (COPD) Exacerbations},
  howpublished = {EasyChair Preprint no. 13686},

  year = {EasyChair, 2024}}